Work

Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases

Year: 2026

Type: article

Abstract: Patients with malignant lymphoma receiving anti-CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID-19), with no established standard treatment. We report three cases of persistent COVID-19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir-based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.

Source: Respirology Case Reports

DOI: 10.1002/rcr2.70804